Delayed
Bombay S.E.
03:49:44 13/12/2021 pm IST
|
5-day change
|
1st Jan Change
|
2.1
INR
|
+5.00%
|
|
-.--%
|
-.--%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,006
|
487.2
|
182.7
|
95.8
|
71.59
|
71.59
|
Enterprise Value (EV)
1 |
1,677
|
1,175
|
931.7
|
110.8
|
86.95
|
87.19
|
P/E ratio
|
738
x
|
22
x
|
-0.38
x
|
-0.4
x
|
-2.36
x
|
-42
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.92
x
|
0.35
x
|
0.17
x
|
488
x
|
73
x
|
-
|
EV / Revenue
|
1.54
x
|
0.84
x
|
0.87
x
|
565
x
|
88.7
x
|
-
|
EV / EBITDA
|
18.2
x
|
9.14
x
|
-3.24
x
|
2.77
x
|
-
|
-
|
EV / FCF
|
-21.7
x
|
-33.4
x
|
7.57
x
|
3.22
x
|
14.6
x
|
249
x
|
FCF Yield
|
-4.61%
|
-3%
|
13.2%
|
31.1%
|
6.86%
|
0.4%
|
Price to Book
|
1.5
x
|
0.7
x
|
0.85
x
|
-4.67
x
|
-1.41
x
|
-1.37
x
|
Nbr of stocks (in thousands)
|
34,091
|
34,091
|
34,091
|
34,091
|
34,091
|
34,091
|
Reference price
2 |
29.50
|
14.29
|
5.360
|
2.810
|
2.100
|
2.100
|
Announcement Date
|
21/10/18
|
18/09/19
|
04/12/20
|
28/02/24
|
26/05/24
|
26/05/24
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,091
|
1,396
|
1,067
|
0.1962
|
0.9804
|
-
|
EBITDA
1 |
92.32
|
128.5
|
-287.4
|
40.01
|
-
|
-
|
EBIT
1 |
53.54
|
88.22
|
-334.5
|
-7
|
-36.51
|
-1.278
|
Operating Margin
|
4.91%
|
6.32%
|
-31.36%
|
-3,567.8%
|
-3,724.4%
|
-
|
Earnings before Tax (EBT)
1 |
8.775
|
33.63
|
-478.3
|
-188.7
|
-30.31
|
-1.571
|
Net income
1 |
1.392
|
21.89
|
-478.3
|
-236.6
|
-30.31
|
-1.571
|
Net margin
|
0.13%
|
1.57%
|
-44.84%
|
-1,20,613.89%
|
-3,091.91%
|
-
|
EPS
2 |
0.0400
|
0.6500
|
-14.03
|
-6.940
|
-0.8900
|
-0.0500
|
Free Cash Flow
1 |
-77.31
|
-35.19
|
123.1
|
34.44
|
5.961
|
0.3497
|
FCF margin
|
-7.08%
|
-2.52%
|
11.54%
|
17,551.36%
|
607.99%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
86.06%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/10/18
|
18/09/19
|
04/12/20
|
28/02/24
|
26/05/24
|
26/05/24
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
672
|
688
|
749
|
15
|
15.4
|
15.6
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
7.276
x
|
5.351
x
|
-2.605
x
|
0.3756
x
|
-
|
-
|
Free Cash Flow
1 |
-77.3
|
-35.2
|
123
|
34.4
|
5.96
|
0.35
|
ROE (net income / shareholders' equity)
|
0.21%
|
3.2%
|
-105%
|
-184%
|
85%
|
3.04%
|
ROA (Net income/ Total Assets)
|
1.96%
|
3.23%
|
-14.9%
|
-0.72%
|
-30.7%
|
-1.5%
|
Assets
1 |
71.15
|
678.1
|
3,219
|
32,763
|
98.82
|
104.7
|
Book Value Per Share
2 |
19.70
|
20.40
|
6.340
|
-0.6000
|
-1.490
|
-1.540
|
Cash Flow per Share
2 |
0.6000
|
0.5900
|
0.2400
|
0.0300
|
0.0200
|
0.0200
|
Capex
1 |
108
|
98.6
|
28.3
|
-
|
-
|
-
|
Capex / Sales
|
9.92%
|
7.06%
|
2.65%
|
-
|
-
|
-
|
Announcement Date
|
21/10/18
|
18/09/19
|
04/12/20
|
28/02/24
|
26/05/24
|
26/05/24
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 858K | | +52.93% | 803B | | +40.98% | 631B | | -7.08% | 351B | | +17.40% | 324B | | +10.58% | 303B | | +16.42% | 243B | | +2.17% | 228B | | +10.66% | 217B | | +6.24% | 164B |
Other Pharmaceuticals
|